 Mr Khan said he feels guilty rather than lucky at not falling ill |
A man who took part in the drug trial which left six seriously ill said he was told he had to return for a follow-up check before he can be paid. Raste Khan, from Barry, near Cardiff, was given a placebo during the trial.
He said he would go without his �2,000 payment rather than return to Northwick Park Hospital to complete the study.
But Drug firm TeGenero said it had already authorised payment. Another firm, Parexel, which conducted the trial, said it was following procedure.
Mr Khan has described the outcome of the drug trial as a "living hell".
The healthy volunteers were testing an anti-inflammatory drug - TGN1412 - at a research unit based at Northwick Park Hospital when they suffered a severe reaction.
It was the first time the drug, designed to treat conditions such as rheumatoid arthritis and leukaemia, had been tested on humans.
Mr Khan, who it emerged was given a placebo, recalled the " living hell" that emerged with minutes of the test beginning.
He witnessed fellow volunteers collapse in agony as they suffered multiple organ failure.
Two of the most critically ill were rushed into intensive care. One of them remains in hospital where is said to be making "steady progress".
On Friday, Mr Khan told BBC Wales that he was called this week and asked to go back. He said the doctor who co-ordinated the trial had told him that he would receive his fee after giving more samples.
He said: "Some people might think I'm going over the top but after what I saw, I've just thought I honestly don't want to step back into that hospital.
"And if it means forfeiting that �2,000, it's going to have to be.
"I'm still trying to catch up on just regular sleep and my emotions are like a rollercoaster at the moment.
"A lot of people say I should feel lucky for what's happened but to be honest with you, I feel more guilty than lucky because I'm pretty sure those people in that hospital would rather be in my position."
TeGenero said it had authorised payments to the trial volunteers to be made last week and that there was no requirement for participants to undergo a further blood test to have the money.
Parexel said they were following standard follow-up procedures.